

Cite this: *Chem. Sci.*, 2025, 16, 6507

All publication charges for this article have been paid for by the Royal Society of Chemistry

Received 7th January 2025

Accepted 7th March 2025

DOI: 10.1039/d5sc00103j

rsc.li/chemical-science

## A dual-enzyme activated fluorescent probe for precise identification of tumor senescence†

Xianzhu Luo,<sup>ab</sup> Erzhuo Hu,<sup>a</sup> Fei Deng,<sup>c</sup> Cuiling Zhang <sup>\*a</sup> and Yuezhong Xian <sup>\*a</sup>

Precise recognition of senescent cells is essential owing to their key role in various diseases, including aging and tumor suppression. Although senescence-associated  $\beta$ -galactosidase (SA- $\beta$ -Gal) is widely used as a senescence biomarker, it is not remarkably accurate due to its overexpression in some non-senescent cells. Herein, we developed a dual-channel fluorescent probe to improve the identification accuracy of senescent cells through simultaneous detection of  $\beta$ -gal and  $\alpha$ -L-fucosidase (AFU) because the two markers are upregulated in senescent cells. The dual-channel fluorescent probe named HDQ-NA-AFU-Gal was employed to detect  $\beta$ -gal and AFU and identify senescence in living cells and tumor-bearing mice. When the two are present, the dual-enzyme activated probe emits strong red and green fluorescence at 740 nm and 550 nm, respectively, enabling independent detection of  $\beta$ -gal and AFU. This dual-enzyme detection approach allows for the precise differentiation between normal and senescent cells, particularly in ovarian cancer cells overexpressing  $\beta$ -gal. Furthermore, the probe can be applied as an effective tool for tracing  $\beta$ -gal and AFU during tumor senescence in mice. Thus, the dual-enzyme-responsive fluorescent probe has promising applications in biological research and clinical medicine.

## Introduction

Cellular senescence has traditionally been defined as a durable arrest of the cell cycle, occurring in response to oxidative stress or exogenous stimuli. The process serves to promote tissue repair and prevent the proliferation of stressed or damaged cells.<sup>1,2</sup> Cellular senescence can be induced by various factors, including DNA damage, telomere dysfunction, oncogene activation, and oxidative stress.<sup>1,3</sup> Recent studies have indicated its involvement in tissue repair and tumor suppression.<sup>4,5</sup> However, accumulating evidence suggests that an abnormal buildup of senescent cells may contribute to the development of age-related diseases, including inflammation, tissue aging, fibrosis, and neurodegenerative diseases.<sup>6,7</sup> For instance, cellular senescence plays a key role in cancer development. On the one hand, it contributes to curbing tumor progression by

inhibiting the proliferation of cancer cells. On the other hand, excessive senescence in cancer cells can lead to a persistent inflammatory environment, which can create a “breeding ground” for tumor development.<sup>8</sup> Therefore, specific monitoring of cancer cells senescence is of great significance.

Several biochemical indicators may be associated with cellular senescence, including the lack of proliferation markers (such as Ki67), elevated levels of  $\beta$ -galactosidase ( $\beta$ -gal) in lysosomes, and the up-regulation or activation of tumor suppressors, *e.g.*, p53, p21, and p16.<sup>9–13</sup> Among them,  $\beta$ -gal is not only easy to detect in cells and tissues but has also become one of the most widely used biomarkers for assessing senescence.<sup>14</sup> However, overexpression of  $\beta$ -gal has also been found in some non-senescent cells, such as ovarian cancer cells (Ovcar-3 cells).<sup>15,16</sup> In some cases, a decrease in  $\beta$ -gal expression does not prevent the occurrence of senescence, as observed in human fibroblasts and cervical cancer cells. These indicated that only the  $\beta$ -gal biomarker is insufficient for the precise detection of cellular senescence.<sup>17,18</sup> As a kind of glycosidase,  $\alpha$ -L-fucosidase (AFU) plays a role in the metabolism of specific glycolipids and glycoproteins, and it has been identified as a promising biomarker for cellular senescence.<sup>19,20</sup> Therefore, the simultaneous detection of dual enzymes ( $\beta$ -gal and AFU) could improve the precision of cell senescence diagnosis.

Compared to co-staining and optical microscopy, fluorescent probes for monitoring biomarkers (such as  $\beta$ -gal) offer some advantages, including non-invasiveness, high sensitivity, and real-time visualization.<sup>21–26</sup> Although it is possible to use

<sup>a</sup>Shanghai Engineering Research Center of Molecular Therapeutics and New Drug Development, Department of Chemistry, School of Chemistry and Molecular Engineering, East China Normal University, Shanghai 200241, China. E-mail: clzhang@chem.ecnu.edu.cn; yzxian@chem.ecnu.edu.cn

<sup>b</sup>Key Laboratory of Haikou Trauma, Key Laboratory of Hainan Trauma and Disaster Rescue, Key Laboratory of Emergency and Trauma, Ministry of Education, The First Affiliated Hospital of Hainan Medical University, Hainan Medical University, Haikou 571199, China

<sup>c</sup>ARC Centre of Excellence for Nanoscale Biophotonics, Graduate School of Biomedical Engineering, Faculty of Engineering, University of New South Wales, Sydney 2052, Australia

† Electronic supplementary information (ESI) available. See DOI: <https://doi.org/10.1039/d5sc00103j>



multiple fluorescent probes to simultaneously detect multiple targets, the differences in probe uptake and localization in the cell might lead to variability in experimental results. The development of one probe with multi-response functions can address these issues.<sup>27</sup>

In recent years, multi-analyte fluorescent probes have received attention for their higher accuracy in related research, including reversible probes,<sup>28,29</sup> AND logic probes,<sup>30,31</sup> sequential detection probes,<sup>32,33</sup> and non-interference fluorescent probes.<sup>34–38</sup> These systems address the challenges of using multiple independent fluorescent probes to understand the relationships between various biological species. However, many fluorescent probes are limited to detect multiple targets individually or simultaneously. And probes may be consumed after reacting with one target, resulting in inaccurate detection of other targets. AND logic systems and sequential detection only provide information about the synergistic effects of two species and do not do so for the independent study of each species. Dual-channel emission should be able to simultaneously evaluate each species' role and study their interactions.<sup>36–38</sup> For example, Wu *et al.* developed a dual-channel fluorescent probe (ATP-LW) that can simultaneously detect peroxynitrite (ONOO<sup>−</sup>) and adenosine-5'-triphosphate (ATP), revealing that an increase in ONOO<sup>−</sup> and ATP depletion are believed to be the causes of liver necrosis.<sup>36</sup> Ren *et al.* monitored endogenous hypochlorous acid (HClO) and hydrogen sulfide (H<sub>2</sub>S) in lysosomes of living cells using a single fluorescent probe with a dual-channel, providing a powerful molecular tool for studying the relationship between redox balance and lysosomal function.<sup>37</sup> Wang *et al.* developed a fluorescent probe for monitoring the dynamic changes of hydrogen peroxide (H<sub>2</sub>O<sub>2</sub>) and glutathione (GSH), elucidating the biochemical mechanism of ferroptosis in different disease models.<sup>38</sup>

Recently, some multi-target recognition fluorescent probes have been developed for the detection of cellular senescence.<sup>39–42</sup> For example, Gao *et al.* developed a fluorescent probe for tracking cellular senescence, relying on detecting senescence-related β-gal activity and monitoring lysosomal pH.<sup>41</sup> Liu *et al.* developed an excellent fluorescent probe based on β-gal, HClO, and lysosomal pH for tracking of cellular senescence.<sup>39</sup> Wang *et al.* reported a dual-locked enzyme-activatable bioorthogonal fluorescence (DEBOF) imaging approach for the detection of senescent cancer cells, allowing tracking of the population fluctuation of senescent cancer cells in tumor-bearing mice.<sup>40</sup> These fluorescent probes are mainly based on AND logical or sequential response, which cannot be used for independent research on each species and evaluation of their interactions. Therefore, it is urgently necessary to develop a multi-target independent detection system for multiple analytes in cellular senescence.

Herein, we successfully designed a dual-target activated fluorescent probe (HDQ-NA-AFU-Gal) for precise imaging of cellular senescence based on β-gal and AFU enzymes. In the presence of β-gal and AFU, the dual-response fluorescent probe emits strong fluorescence signals at 740 nm and 550 nm, respectively, enabling the simultaneous and non-interfering detection of both enzymes. This approach not only effectively

avoids spectral overlap but also studies the roles and interactions between each species. The biocompatible HDQ-NA-AFU-Gal exhibits high specificity and sensitivity for β-gal and AFU. Moreover, the probe can be effectively localized in lysosomes. This probe can distinguish senescent cells from non-senescent cells based on the high expression of β-gal or AFU, such as human hepatoma cells (HepG2 cells), Ovar-3 cells, and mouse breast 4T1 tumor cells. Furthermore, HDQ-NA-AFU-Gal has been successfully applied in tracing the activity of β-gal and AFU during tumor senescence in mice.

## Results and discussion

### Design and synthesis of the fluorescent HDQ-NA-AFU-Gal probe

A fluorescent probe (HDQ-NA-AFU-Gal) was rationally designed to detect β-gal and AFU separately or simultaneously. The synthesis route is illustrated in Scheme S1.† The naphthylimide scaffold was modified by introducing α-L-fucose as a specific recognition group for AFU. To enable simultaneous detection of β-gal, we incorporated β-D-galactopyranoside and hemi-carbocyanine moieties as the responsive and fluorescent moieties of β-gal, respectively. When β-gal and AFU are present, the probe exhibits significant red and green fluorescence at 740 nm and 550 nm, respectively, enabling independent detection of β-gal and AFU. When both AFU and β-gal are present, the probe emits strong fluorescence at 550 nm and 740 nm, respectively. The dual-enzyme activation probe enhances the accuracy of tracking cell senescence. The HDQ-NA-AFU-Gal probe was characterized by nuclear magnetic resonance (NMR) and mass spectrometry (MS). The NMR and MS results (*m/z* [C<sub>53</sub>H<sub>54</sub>N<sub>3</sub>O<sub>15</sub>]<sup>+</sup>, calcd: 972.3545; found [M + Na]<sup>+</sup>: 995.3380) indicated the successful synthesis of the probe.

### Absorption spectra of the HDQ-NA-AFU-Gal probe towards β-gal and AFU

UV-vis absorption spectra of the HDQ-NA-AFU-Gal probe were recorded in PBS (10 mM, pH = 6) containing 5% DMSO as a co-solvent. As shown in Fig. S1,† the probe exhibited a strong absorption peak at 470 nm. Upon the addition of AFU, a new absorption peak around 420 nm appeared, which was attributed to the hydrolysis of α-L-fucopyranoside by AFU, which resulted in the release of the naphthalimide fluorophore (Scheme 1). Subsequently, the addition of β-gal led to the cleavage of β-D-pyranose lactoside and release of the phthalocyanine fluorophore. This caused a reduction of the absorption at 470 nm and an increase of the absorption at 620 nm. When both enzymes were present, the absorption peak at 470 nm completely disappeared, and strong absorption peaks at 420 nm and 620 nm appeared. These results indicate that the probe can be used for detecting β-gal and AFU separately or simultaneously.





**Scheme 1** Dual-enzyme activated fluorescent probe for precise identification of senescence. (A) Design and mechanism of the dual-enzyme activated fluorescent probe. (B) Distinguishing senescent cells based on overexpressed  $\beta$ -gal and AFU. (C) Tracking tumor senescence in mice.

### Fluorescence spectra of HDQ-NA-AFU-Gal toward $\beta$ -gal and AFU


We further investigated the fluorescence of HDQ-NA-AFU-Gal towards  $\beta$ -gal and AFU. As shown in Fig. 1A and D, the probe exhibited minimal fluorescence at 550 nm and 740 nm under excitation at 450 nm and 640 nm, respectively. Upon the addition of AFU and  $\beta$ -gal, we observed the fluorescence enhancement of the probe at 550 nm ( $\lambda_{\text{ex}} = 450 \text{ nm}$ ) and 740 nm ( $\lambda_{\text{ex}} =$

640 nm), respectively, which indicated that the probe could be used for the detection of AFU and  $\beta$ -gal. Moreover, a linear relationship was observed between the fluorescence intensity of the probe and the concentrations of AFU (2–100 U per L) and  $\beta$ -gal (5–500 U per L) (Fig. 1B and E). The corresponding linear equations were  $Y_1 = 10.2356 [\text{AFU}] + 34.4198 \text{ (U per L)}$  ( $R_1^2 = 0.9985$ ) and  $Y_2 = 0.6033 [\beta\text{-gal}] - 0.1197 \text{ (U per L)}$  ( $R_2^2 = 0.9983$ ), respectively. The detection limits for AFU and  $\beta$ -gal, based on  $3\sigma/k$  (where  $\sigma$  is the standard deviation and  $k$  is the slope), were about 0.32 U per L and 2.80 U per L, respectively. In addition, we investigated the stability of the probe in different physiological environments. The probe remained stable in PBS buffer or FBS containing solution at 37 °C, and almost no decomposition was observed (Fig. S2 and S3†).

Subsequently, we investigated whether the probe could be used for the simultaneous detection of  $\beta$ -gal and AFU. As shown in Fig. S4A,† in the presence of 500 U per L  $\beta$ -gal, the fluorescence intensity was enhanced with the increase of AFU concentration, indicating that the detection of AFU was not affected by  $\beta$ -gal. As shown in Fig. S4B,† the presence of AFU did not interfere with the detection of  $\beta$ -gal. These results indicate that the probe enables separate or simultaneous detection of  $\beta$ -gal and AFU through dual channels without cross-interference.

### Selectivity of the HDQ-NA-AFU-Gal probe for $\beta$ -gal and AFU

We investigated the selectivity of HDQ-NA-AFU-Gal for  $\beta$ -gal and AFU by examining the probe's responsiveness to various biological species, including carboxylic esterase, BSA (100  $\mu\text{g mL}^{-1}$ ), alkaline phosphatase (ALP, 1 U  $\text{mL}^{-1}$ ), common amino acids (cysteine (Cys), glutathione (GSH), tryptophan (Try),



**Fig. 1** The changes of fluorescence spectra of the HDQ-NA-AFU-Gal probe for  $\beta$ -gal (5–500 U per L) and AFU (1–100 U per L) in DMSO : PBS buffer (1 : 9, v/v). Fluorescence spectra of HDQ-NA-AFU-Gal against (A) AFU and (D)  $\beta$ -gal, respectively. Corresponding linear response of the probe against (B) AFU and (E)  $\beta$ -gal, respectively. Selectivity of the probe for (C) AFU and (F)  $\beta$ -gal at emission wavelengths of 550 nm and 740 nm, respectively. (1) Blank, (2) AFU (100 U per L), (3)  $\beta$ -gal (500 U per L), (4) esterase (0.5 U  $\text{mL}^{-1}$ ), (5) BSA (100  $\mu\text{g mL}^{-1}$ ), (6) ALP (1 U  $\text{mL}^{-1}$ ), (7) Cys (1 mM), (8) GSH (1 mM), (9) Hcy (1 mM), (10) HClO (100  $\mu\text{M}$ ), (11)  $\text{NO}_2^-$  (100  $\mu\text{M}$ ), and (12)  $\text{H}_2\text{O}_2$  (100  $\mu\text{M}$ ).



methionine (Met), leucine (Leu), threonine (Thr), glycine (Gly), and alanine (Ala)), several active small molecular species ( $\text{H}_2\text{O}_2$ ,  $\text{ClO}^-$ , and  $\text{NO}_2^-$ ), and common ions ( $\text{Fe}^{3+}$ ,  $\text{Ca}^{2+}$ ,  $\text{Mg}^{2+}$ ,  $\text{Zn}^{2+}$ ,  $\text{SO}_4^{2-}$ ,  $\text{CO}_3^{2-}$ , and  $\text{NO}_3^-$ ). The results showed that only AFU induced a strong fluorescence signal change at 550 nm, while the other substances did not result in significant fluorescence changes (Fig. 1C and S5A†). Furthermore, only  $\beta$ -gal caused a noticeable fluorescence signal change at 740 nm (Fig. 1F and S5B†). These results suggest that the probe exhibits excellent specificity for  $\beta$ -gal and AFU.

### Reaction kinetics of HDQ-NA-AFU-Gal towards $\beta$ -gal and AFU

We then investigated the fluorescence kinetics of the HDQ-NA-AFU-Gal probe towards targets. As shown in Fig. S6A,† in the presence of AFU, the fluorescence intensity of HDQ-NA-AFU-Gal at 550 nm increased with prolonged reaction time and then reached a maximum around 45 min. We also tested the change in the fluorescence signal of the HDQ-NA-AFU-Gal probe in the presence of  $\beta$ -gal with reaction time. The fluorescence intensity at 740 nm showed an increase with reaction time and then remained stable after approximately 25 min (Fig. S6B†).

### Effect of pH on the performance of HDQ-NA-AFU-Gal

We further assessed the effect of pH (ranging from 4 to 9) on the fluorescence signal of the HDQ-NA-AFU-Gal probe for detecting AFU and  $\beta$ -gal. As shown in Fig. S7,† in the absence of AFU and  $\beta$ -gal, the probe exhibited negligible fluorescence at both 550 nm and 740 nm. Upon the addition of AFU, the fluorescence signal at 550 nm gradually increased with the increase of pH and reached a maximum at pH 6 before the plateau (Fig. S7A†). Conversely, in the presence of 500 U per L  $\beta$ -gal, the fluorescence signal at 740 nm decreased slowly with increasing pH, remaining relatively stable at pH 4–6 (Fig. S7B†). Given that  $\beta$ -gal and AFU are primarily localized in weak acidic lysosomes, this probe exhibits great potential for monitoring their activity.

### HDQ-NA-AFU-Gal probe for the detection of $\beta$ -gal and AFU in living cells

We assessed the feasibility of this probe for the detection of  $\beta$ -gal and AFU in biological systems. Firstly, we tested its cytotoxicity using the CCK-8 assay. As shown in Fig. S8,† when the concentration of HDQ-NA-AFU-Gal was at 50  $\mu\text{M}$ , all cell lines ( $\text{LO}_2$ , 4T1, Ovar-3 and HepG2 cells) exhibited high viability, indicating that the HDQ-NA-AFU-Gal probe has low cytotoxicity.

We further investigated whether HDQ-NA-AFU-Gal could be used to monitor  $\beta$ -gal and AFU in living cells using laser confocal scanning microscopy. Previous studies have demonstrated that  $\beta$ -gal and AFU were overexpressed in Ovar-3 and HepG2, respectively. Thus, we selected these two cell lines as the models.  $\text{LO}_2$  cells were used as a negative control with relatively low levels of  $\beta$ -gal and AFU. First, we tested the incubation time of the probe to detect  $\beta$ -gal and AFU in different cell lines. As shown in Fig. S9 and S10,† both the green and red fluorescence signals gradually increased with time and then remained stable after around 60 min. Therefore, we selected 60 min as the optimal incubation time. As shown in Fig. 2A, the probe



Fig. 2 (A) Confocal fluorescence images of  $\beta$ -gal and AFU in  $\text{LO}_2$ , HepG2 and Ovar-3 cells, respectively. Relative fluorescence intensity of corresponding cell lines obtained from (B) green and (C) red channels, respectively. Scale bar: 50  $\mu\text{m}$ . Green channel, 500–560 nm ( $\lambda_{\text{ex}} = 488$  nm), and red channel, 700–780 nm ( $\lambda_{\text{ex}} = 640$  nm). Scale bar: 50  $\mu\text{m}$ .

exhibited weak green and red fluorescence in  $\text{LO}_2$  cells. In contrast, a significant green fluorescence signal was observed in HepG2 cells with overexpressed AFU, indicating that the probe can be used for the detection of AFU in living cells. Subsequently, we investigated the performance of the probe for monitoring  $\beta$ -gal. A strong red and a slightly enhanced green fluorescent signal were detected in Ovar-3 cells compared to  $\text{LO}_2$  cells, confirming that the probe can effectively detect  $\beta$ -gal in Ovar-3 cells. These results demonstrate that the probe can simultaneously detect  $\beta$ -gal and AFU in living cells.

### Lysosomal co-localization studies

Given that AFU and  $\beta$ -gal are primarily localized in the lysosomes of cells, we further explored whether the probe could be localized in the lysosomes of living cells. The pyridine nitrogen



Fig. 3 Lysosomal colocalization for Lyso-Tracker Green and HDQ-NA-AFU-Gal stained Ovar-3 cells. (A) Fluorescence images of Ovar-3 cells co-incubated with HDQ-NA-AFU-Gal and Lyso-Tracker Green (from left to right, merged image, green and red channel images, respectively). (B) Magnified images of regions of interest in square frames shown in (A). (C) Colocalization scatter diagram of the color mode for red and green channels in (B). (D) Intensity distribution map and colocalization curves across the regions of interest in the green and red channels indicated by the yellow arrows in (B). Green channel: 500–560 nm ( $\lambda_{\text{ex}} = 488$  nm) and red channel: 680–770 nm ( $\lambda_{\text{ex}} = 640$  nm).



atom in the probe with excellent acidophilic properties makes it a potential candidate for lysosome targeting.<sup>43</sup> We then used the commercial lysosomal dye Lyso-Tracker Green as a control in co-localization experiments. We chose Ovar-3 cells as the model and co-incubated with Lyso-Tracker Green and HDQ-NA-AFU-Gal probe. As shown in Fig. 3A and B, a strong correlation was observed between the green fluorescence channel of Lyso-Tracker Green and the red channel of HDQ-NA-AFU-Gal, with a Pearson's correlation coefficient of 0.86. Furthermore, a high degree of fluorescence synchronization was evident between the green channel of Lyso-Tracker Green and the red channel of HDQ-NA-AFU-Gal, as analyzed at the site indicated by the white box and the yellow arrow. These results indicate that the HDQ-NA-AFU-Gal probe can be efficiently localized in the lysosomes of cells.

#### HDQ-NA-AFU-Gal probe for detection of $\beta$ -gal and AFU in senescent cells

The ability of HDQ-NA-AFU-Gal to monitor AFU and  $\beta$ -gal in senescent cells was further investigated using laser confocal scanning microscopy. We selected two cell lines with low expression of AFU and  $\beta$ -gal: a normal cell line (LO<sub>2</sub> cells) and a breast cancer cell line (4T1 cells). In addition, we also studied

other cell lines, such as HepG2 cells overexpressing AFU and Ovar-3 cells overexpressing  $\beta$ -gal. Different methods were employed to induce cellular senescence in these cell lines. We pretreated LO<sub>2</sub> cells and HepG2 with H<sub>2</sub>O<sub>2</sub> for 3 days to induce senescence.<sup>20</sup> As for 4T1 cells, they were treated with palbociclib,<sup>13</sup> a common breast cancer kinase inhibitor, for one week.<sup>44,45</sup> For Ovar-3 cells, the cells were co-incubated with doxorubicin (DOX, 0.5  $\mu$ M) for 3 days to induce senescence. To validate the successful induction of cellular senescence, we used a commercially available senescence kit (X-gal) to test (Fig. 4A). A strong blue signal is observed in senescent cells after using X-gal, while almost no signal was detected in non-senescent cells.<sup>46</sup> After treatment with H<sub>2</sub>O<sub>2</sub> or palbociclib, we observed a distinct blue signal in both LO<sub>2</sub> and 4T1 cells, confirming the successful establishment of the senescence models. In addition, we tested the levels of cell cycle-related factors (such as p21 and p16) and some typical senescence-associated secretory phenotypes (IL-6, IL-1 $\beta$ ) (Fig. 4D, S11 and S12<sup>†</sup>). The results showed that the levels of p21, P16, IL-6 and IL-1 $\beta$  were upregulated, further demonstrating the successful establishment of the cell senescence model.

As shown in Fig. 4B, untreated LO<sub>2</sub> and 4T1 cells displayed weak fluorescence in green and red channels. After H<sub>2</sub>O<sub>2</sub> or



**Fig. 4** HDQ-NA-AFU-Gal probe for the detection of AFU and  $\beta$ -gal in normal or senescent LO<sub>2</sub> cells, 4T1 cells, HepG2 cells and Ovar-3 cells. (A) Commercial SA- $\beta$ -gal staining kit for the detection of  $\beta$ -gal in normal or senescent LO<sub>2</sub>, 4T1, HepG2 and Ovar-3 cells. (B) Fluorescence imaging with the HDQ-NA-AFU-Gal probe for the tracking of AFU and  $\beta$ -gal in different cell lines. (C) Average fluorescence intensity in (B). (D) Western blotting analysis of p21 and p16 levels in different groups in (B). Green channel: 500–560 nm ( $\lambda_{\text{ex}} = 488$  nm) and red channel: 680–770 nm ( $\lambda_{\text{ex}} = 640$  nm). Scale bar: 50  $\mu$ m. Error bars represent mean  $\pm$  S.D. from four independent replicates. Statistical significance was calculated using one way ANOVA by Tukey's multiple comparison test. \* $p < 0.05$ , \*\* $p < 0.01$ , \*\*\* $p < 0.001$ , and ns: no significant difference.





**Fig. 5** Fluorescence imaging using the dual-channel probe in 4T1 tumor-bearing balb/c female mice with/without palbociclib. (A) H&E and (B) Ki67 tissue staining. *In vivo* (C) and tissue (D) fluorescence images of control and 4T1 tumor-bearing BALB/c female mice orally administered with palbociclib (senescent tumor mice). Histogram of relative fluorescence intensity of (E) mice and (F) tissue. Error bars represent mean  $\pm$  S.D. from four independent replicates. Statistical significance was calculated using one way ANOVA by Tukey's multiple comparison test. \* $p < 0.05$ , \*\* $p < 0.01$ , \*\*\* $p < 0.001$ .

palbociclib treatment, both cell lines exhibited obvious fluorescence in the green and red channels (Fig. 4B and C), suggesting the elevation of AFU and  $\beta$ -gal in senescent normal and cancer cells. In addition, both HepG2 cells overexpressing AFU and Ovar-3 cells overexpressing  $\beta$ -gal showed strong red and green fluorescence signals after induction of cellular senescence. These results further implied that the HDQ-NA-AFU-Gal probe could be used for monitoring cellular senescence. Overall, the probe can be used to differentiate different senescent cells by detecting the levels of AFU and  $\beta$ -gal, thereby enhancing the accuracy of senescent cell detection, avoiding the inaccuracy of identifying cellular aging solely through  $\beta$ -gal detection.

#### HDQ-NA-AFU-Gal probe for imaging of AFU and $\beta$ -gal during tumor senescence

Based on the excellent performance of the dual-channel fluorescence HDQ-NA-AFU-Gal probe in living cells, we then investigated the feasibility of the probe in a tumor senescence mouse model. Balb/c mice were divided into two groups: the control group (4T1 tumor mice) and the treatment group (4T1 tumor mice treated with palbociclib). A tumor-bearing mouse model was first established by subcutaneously injecting 4T1 cells. For the treatment group, mice were treated with palbociclib daily for 7 days to induce senescence and inhibit tumor growth.

The successful establishment of the tumor model was initially validated through H&E staining (Fig. 5A). Additionally, the absence of the proliferation marker Ki67 further confirmed tumor senescence (Fig. 5B), suggesting the effective induction of senescence in the tumor. Subsequently, *in vivo* fluorescence imaging based on the probe was performed. In the control group, weak fluorescence signals were observed in the tumor region, whereas significantly enhanced fluorescent signals in green and red fluorescent channels were observed in the treatment group. These results suggest that the probe can effectively

detect AFU and  $\beta$ -gal in tumor senescence (Fig. 5C), and can be used to assess tumor treatment effects through monitoring AFU and  $\beta$ -gal levels. Fresh tumor sections were then imaged and analyzed using confocal microscopy. As shown in Fig. 5D, the control group displayed only weak fluorescence in both channels. In contrast, the treatment group exhibited strong fluorescent signals in both green and red channels. These results indicate that HDQ-NA-AFU-Gal can be employed for precise detection of tumor senescence, providing an effective tool for monitoring senescence *in vivo*.

## Conclusions

In summary, we have successfully developed a dual-enzyme activated fluorescent probe, HDQ-NA-AFU-Gal, for tracking senescence *in vivo*. HDQ-NA-AFU-Gal shows the features of separate or simultaneous detection of AFU and  $\beta$ -gal without cross-talking. In the presence of AFU and  $\beta$ -gal, the probe emits strong fluorescence at 550 nm and 740 nm, respectively, demonstrating high sensitivity and specificity towards AFU and  $\beta$ -gal. Based on dual response design, HDQ-NA-AFU-Gal can effectively distinguish  $\beta$ -gal or AFU overexpressed cells and senescent cells, thereby improving the accuracy and precision of aging diagnosis. In addition, the probe has been successfully applied in imaging tumor senescence, providing a new strategy for the evaluation of senescence and assessment of potential tumor treatment.

## Data availability

Additional experimental data supporting this article are included in the ESI.† Reasonable requests for additional information can be made to the corresponding authors.



## Author contributions

Xianzhu Luo: conceptualization, investigation, writing – original draft. Erzhuo Hu: investigation, visualization. Cuiling Zhang: supervision, conceptualization, writing – review & editing, funding acquisition. Yuezhong Xian: supervision, writing – review & editing, funding acquisition.

## Conflicts of interest

There are no conflicts to declare.

## Acknowledgements

This research was supported by the National Natural Science Foundation of China (22274054, 21974050, and 11727810), the Natural Science Foundation of Shanghai (20ZR1418000), and the Fundamental Research Funds for the Central Universities. All animal procedures were performed in accordance with the Guidelines for Care and Use of Laboratory Animals of East China Normal University and approved by the Animal Ethics Committee of East China Normal University (No. m20240204).

## References

- M. Collado, M. A. Blasco and M. Serrano, *Cell*, 2007, **130**, 223–233.
- D. Muñoz-Espín and M. Serrano, *Nat. Rev. Mol. Cell Biol.*, 2014, **15**, 482–496.
- S. He and N. E. Sharpless, Senescence in Health and Disease, *Cell*, 2017, **169**, 1000–1011.
- M. Rhinn, B. Ritschka and W. M. Keyes, *Development*, 2019, **146**, dev151837.
- L. Yang, G. Liu, Q. Chen, Y. Wan, Z. Liu, J. Zhang, C. Huang, Z. Xu, S. Li, C. Lee, L. Zhang and H. Sun, *Anal. Chem.*, 2022, **94**, 5425–5431.
- J. L. Kirkland, T. Tchkonina, Y. Zhu, L. J. Niedernhofer and P. D. Robbins, *J. Am. Geriatr. Soc.*, 2017, **65**, 2297–2301.
- L. J. Niedernhofer and P. D. Robbins, *Nat. Rev. Drug Discovery*, 2018, **17**, 377.
- L. Wang, L. Lankhorst and R. Bernards, *Nat. Rev. Cancer*, 2022, **22**, 340–355.
- B. Lozano-Torres, J. F. Blandez, I. Galiana, J. A. Lopez-Dominguez, M. Rovira, M. Paez-Ribes, E. Gonzalez-Gualda, D. Munoz-Espin, M. Serrano, F. Sancenon and R. Martinez-Manez, *Anal. Chem.*, 2021, **93**, 3052–3060.
- M. Serrano, A. W. Lin, M. E. McCurrach, D. Beach and S. W. Lowe, *Cell*, 1997, **88**, 593–602.
- N. E. Sharpless and C. J. Sherr, *Nat. Rev. Cancer*, 2015, **15**, 397–408.
- A. Takahashi, N. Ohtani and E. Hara, *Cell Div.*, 2007, **2**, 10–15.
- B. Lozano-Torres, J. F. Blandez, I. Galiana, A. Garcia-Fernandez, M. Alfonso, M. D. Marcos, M. Orzaez, F. Sancenon and R. Martinez-Manez, *Angew. Chem., Int. Ed.*, 2020, **59**, 15152–15156.
- G. P. Dimri, X. Lee, G. Basile, M. Acosta, G. Scott, C. Roskelley, E. E. Medrano, M. Linskens, I. Rubelj and O. Pereira-Smith, *Proc. Natl. Acad. Sci. U. S. A.*, 1995, **92**, 9363–9367.
- J. Wang, M. Liu, X. Zhang, X. Wang, M. Xiong and D. Luo, *Exploration*, 2024, **4**, 20230027.
- T. Su, R. Shen, D. Tu, X. Han, X. Luo and F. Yu, *Smart Mol.*, 2025, e20240062.
- S. Chatterjee, M. Bhattacharya and J. Barlow, *J. Cancer Res.*, 1979, **39**, 1943–1951.
- H.-G. Kopp, A. T. Hooper, S. V. Shmelkov and S. Rafii, *Histol. Histopathol.*, 2007, **22**, 971–976.
- S. Koo, M. Won, H. Li, W. Y. Kim, M. Li, C. Yan, A. Sharma, Z. Guo, W. H. Zhu, J. L. Sessler, J. Y. Lee and J. S. Kim, *Chem. Sci.*, 2021, **12**, 10054–10062.
- D. Hildebrand, S. Lehle, A. Borst, S. Haferkamp, F. Essmann and K. Schulze-Osthoff, *Cell Cycle*, 2013, **12**, 1922–1927.
- B. Lozano-Torres, I. Galiana, M. Rovira, E. Garrido, S. Chaib, A. Bernardos, D. Munoz-Espin, M. Serrano, R. Martinez-Manez and F. Sancenon, *J. Am. Chem. Soc.*, 2017, **139**, 8808–8811.
- X. Chai, H. H. Han, A. C. Sedgwick, N. Li, Y. Zang, T. D. James, J. Zhang, X. L. Hu, Y. Yu, Y. Li, Y. Wang, J. Li, X. P. He and H. Tian, *J. Am. Chem. Soc.*, 2020, **142**, 18005–18013.
- X. Li, W. Qiu, J. Li, X. Chen, Y. Hu, Y. Gao, D. Shi, X. Li, H. Lin, Z. Hu, G. Dong, C. Sheng, B. Jiang, C. Xia, C.-Y. Kim, Y. Guo and J. Li, *Chem. Sci.*, 2020, **11**, 7292–7301.
- J. Li, L. Wang, X. Luo, Y. Xia, Y. Xie, Y. Liu and W. Tan, *Anal. Chem.*, 2023, **95**, 3996–4004.
- D. Liu, G. Fang, Y. Wang, C. Meng, Z. Liu, Q. Chen and X. Shao, *Exploration*, 2024, **4**, 20230145.
- X. Luo, S. Cheng, W. Zhang, K. Dou, R. Wang, R. Wang and F. Yu, *ACS Sens.*, 2024, **9**, 810–819.
- L. Zhou, X. Zhang, Y. Dong, Y. Pan, J. Li, Y. Zang and X. Li, *ACS Sens.*, 2022, **7**, 1958–1966.
- F. Yu, P. Li, B. Wang and K. Han, *J. Am. Chem. Soc.*, 2013, **135**, 7674–7680.
- L. He, L. He, S. He, T. Xu, X. Ren, Z. Zhang, Z. Qin, X. Zhang and L. Yuan, *Angew. Chem., Int. Ed.*, 2022, **61**, e202211409.
- A. C. Sedgwick, H. H. Han, J. E. Gardiner, S. D. Bull, X. He and T. D. James, *Chem. Sci.*, 2018, **9**, 3672–3676.
- J. Guo, J. Sun, D. Liu, J. Liu, L. Gui, M. Luo, D. Kong, S. Wusiman, C. Yang, T. Liu, Z. Yuan and R. Li, *Anal. Chem.*, 2023, **95**, 16868–16876.
- S. Yang, J. Jiang, A. Zhou, Y. Zhou, W. Ye, D. Cao and R. Yang, *Anal. Chem.*, 2020, **92**, 7194–7199.
- X. Xie, Y. Liu, G. Liu, Y. Zhao, J. Bian, Y. Li, J. Zhang, X. Wang and B. Tang, *Anal. Chem.*, 2022, **94**, 10213–10220.
- Y. Chen, Z. Hu, M. Yang, J. Gao, J. Luo, H. Li and Z. Yuan, *Sens. Actuators, B*, 2022, **362**, 131742.
- Y. Zheng, X. Li, W. Tang, L. Xie, F. Dai and B. Zhou, *Sens. Actuators, B*, 2022, **368**, 132169.
- L. Wu, J. Liu, X. Tian, R. R. Groleau, B. Feng, Y. Yang, A. C. Sedgwick, H. Han, Y. Wang, H. Wang, F. Huang, S. D. Bull, H. Zhang, C. Huang, Y. Zang, J. Li, X. He, P. Li,



- B. Tang, T. D. James and J. L. Sessler, *J. Am. Chem. Soc.*, 2022, **144**, 174–183.
- 37 Y. Wang, H. Yan, Y. Yue, Y. Zhang, F. Huo, F. Cheng and C. Yin, *Chem. Eng. J.*, 2023, **464**, 496.
- 38 M. Ren, Z. Li, B. Deng, L. Wang and W. Lin, *Anal. Chem.*, 2019, **91**(4), 2932–2938.
- 39 H. Liu, R. Lv, F. Song, Y. Yang, F. Zhang, L. Xin, P. Zhang, Q. Zhang and C. Ding, *Chem. Sci.*, 2024, **15**, 5681–5693.
- 40 X. Wang, S. S. Liew, J. Huang, Y. Hu, X. Wei and K. Pu, *J. Am. Chem. Soc.*, 2024, **146**, 22689–22698.
- 41 Y. Gao, Y. Hu, Q. Liu, X. Li, X. Li, C. Y. Kim, T. D. James, J. Li, X. Chen and Y. Guo, *Angew. Chem., Int. Ed.*, 2021, **60**, 10756–10765.
- 42 L. Wang, J. Li, Z. Zhao, Y. Xia, Y. Xie, D. Hong, Y. Liu and W. Tan, *Anal. Chem.*, 2024, **96**, 154–162.
- 43 Y. Wang, R. Zhao, X. Zhu, H. Gao, C. Gong, X. Liu and H. Zhang, *Anal. Chem.*, 2022, **94**, 13413–13421.
- 44 F. Wu, J. Liu, M. Tao, M. Wang, X. Ren and Z. Hai, *Anal. Chem.*, 2023, **95**, 10481–10485.
- 45 S. R. Whittaker, A. Mallinger, P. Workman and P. A. Clarke, *Pharmacol. Ther.*, 2017, **173**, 83–105.
- 46 J. Gao, F. Li, J. Chen, Y. Gao, C. Fan, Y. Huang, H. Yu, X. Yang and X. Wang, *Sens. Actuators, B*, 2024, **398**, 134696.

